Navigation Links
New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product
Date:7/8/2009

Leading personal injury law firm files complaint, alleging permanent damage to Long Island man's sense of smell and taste

Mineola, N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman, senior partner of leading national personal injury law firm of Sanders Viener Grossman, LLP, in Mineola, N.Y., today announced that his firm has filed a civil lawsuit against the manufacturer of the popular Zicam nasal spray and the national drugstore chain that sold the product to a New York man who is alleging permanent injuries from his use of Zicam.

The lawsuit, Coleman et al v. Matrixx Intiatives, Inc. et al (Case Number 2:09-cv-2838), was filed last Thursday in the U.S. District Court, Eastern District of New York. The complaint alleges that Donald Coleman, a Bohemia, N.Y. resident, purchased a bottle of "Zicam Cold Remedy Nasal Spray" at a CVS Pharmacy store. After using the spray for about a week, and although the label stated it was "safe and effective" and a "patented homeopathic" remedy for cold symptoms, Mr. Coleman claims that he permanently lost his senses of smell and taste.

On June 16, 2009, the U.S. Food and Drug Administration (FDA) issued a public health advisory warning consumers to stop using and discard Zicam Cold Remedy Nasal Spray products, because the agency received greater than 130 reports of Anosmia, the medical term for a loss of smell and taste. As an over-the-counter product, neither the Zicam Cold Remedy Nasal Spray nor its labeling has ever been approved by the FDA.

"This is a clear example of an unregulated and unsafe product masquerading as a product that promotes good health" said Mr. Grossman, who is representing Mr. Coleman and numerous other individuals who used Zicam. "Rather than a minor cold, Mr. Coleman now has a permanent injury that deprives him of enjoying foods and aromas that he loved. The suspected culprit is zinc gluconate, listed as the active ingredient in Zicam products."

According to Mr. Grossman, zinc has long been purported as a cure for the common cold, but clinical studies dating back to 1937 have demonstrated that the application of substances containing zinc ions to the lining of the sinuses is toxic to cells that act as "smell receptors." As these cells die, so does not only one's sense of smell, but also taste.

Sanders Viener Grossman, LLP is one of the largest national law firms specializing in protecting the rights of innocent victims who have suffered personal injury as the result of the negligence of others. The firm is well-known for its successful litigation in a wide range of personal injury and products liability cases involving allegedly defective drugs, including headline-grabbing matters against Pfizer, Merck and other leading pharmaceutical companies.

For more information about Sanders Viener Grossman, LLP, please visit www.thesandersfirm.com or call 1.800.FAIRPLAY.

###

Read the full story at http://www.prweb.com/releases/2009/07/prweb2611684.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. CareFusion Files Amended Form 10 Registration Statement With SEC
2. Novo Nordisk Insulin Analogs Have Proven Safety Profiles
3. Discus Dental Files Suit to Protect BriteSmile(R) Trademark
4. WuXi PharmaTech Files 2008 Annual Report on Form 20-F
5. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
6. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
7. Watson Files FDA Application for Generic Mucinex(R) D
8. Profiles International Releases New Report on Top 5 Management Failures and Remedies for Success
9. Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
10. CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS)
11. Mindray Files Annual Report on Form 20-F with U.S. Securities and Exchange Commission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, ... Over the past 20 years SFI has been recognized as the world’s leader in ... clients into the US market. The new clients include: Panacea Pro, Campseekers, Contentmart, ...
(Date:1/19/2017)... ... 2017 , ... Each year, the Southeastern Society of Plastic ... of surgeons from over fifteen different countries come together to share and learn ... to breast reconstruction for breast cancer patients, teaching these surgical techniques which ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting ... global discussion about the benefits of fidgeting to relieve stress and anxiety. No ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... it from the number one doctor-recommended OTC antiperspirant, Certain Dri. , Excessive sweating ... untreated. , Certain Dri created this infographic to explain the seven types of ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... industry’s leading journal and most-read publication among specialty pharmacists and pharmacy professionals, ... through its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... 2017   Regenicin, Inc. (OTC Bulletin Board: ... the development and commercialization of regenerative cell therapies to ... reported the Company,s operating results for 2016 and an ... the Company described in its recent 10-K filing with ... accomplishments. The Company,s contract laboratory completed its evaluation of ...
(Date:1/18/2017)... DAVOS , Suiza, 18 de enero de 2017 ... biofarmacéuticas líderes lanzaron Access Accelerated, una iniciativa global para ... comunicables (NCD) y atención en países de renta baja ... NCD han alcanzado un punto de crisis, particularmente en ... casi el 80 por ciento de las muertes relacionadas ...
Breaking Medicine Technology: